如何治疗激素受体阳性、人表皮生长因子受体2扩增的乳腺癌。 - Suppr

Suppr

超能文献

How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.

作者信息

Cortes Javier, Baselga José

出版信息

J Clin Oncol. 2009 Nov 20;27(33):5492-4. doi: 10.1200/JCO.2009.23.8089. Epub 2009 Sep 28.

DOI:10.1200/JCO.2009.23.8089

PMID:19786653

Abstract

摘要

相似文献

How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.如何治疗激素受体阳性、人表皮生长因子受体2扩增的乳腺癌。

J Clin Oncol. 2009 Nov 20;27(33):5492-4. doi: 10.1200/JCO.2009.23.8089. Epub 2009 Sep 28.

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.曲妥珠单抗联合阿那曲唑对比阿那曲唑单药治疗人表皮生长因子受体 2 阳性、激素受体阳性转移性乳腺癌绝经后女性患者：来自随机 III 期 TAnDEM 研究的结果。

J Clin Oncol. 2009 Nov 20;27(33):5529-37. doi: 10.1200/JCO.2008.20.6847. Epub 2009 Sep 28.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.来曲唑联合拉帕替尼对比来曲唑联合安慰剂作为绝经后激素受体阳性转移性乳腺癌的一线治疗。

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

[Therapy concept: herceptin in combination with arimidex].

Onkologie. 2002 Dec;25 Suppl 5:22 ; discussion 22-4.

Inappropriate ATAC on tamoxifen.他莫昔芬治疗时出现的不适当的雄激素阻断治疗（ATAC）

Lancet Oncol. 2008 Apr;9(4):315-6. doi: 10.1016/S1470-2045(08)70085-8.

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.激素疗法在HER2共表达的激素受体阳性乳腺癌治疗中的作用。

Nat Clin Pract Oncol. 2008 Sep;5(9):531-42. doi: 10.1038/ncponc1179. Epub 2008 Jul 8.

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.用于HER2/neu过表达乳腺癌的蒽环类-曲妥珠单抗治疗方案：当前经验与未来策略。

Ann Oncol. 2008 Sep;19(9):1530-9. doi: 10.1093/annonc/mdn292. Epub 2008 May 13.

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.

J Clin Oncol. 2008 Jul 10;26(20):3301-2. doi: 10.1200/JCO.2008.16.3972. Epub 2008 May 19.

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.在绝经后 HR(+)、HER2(-)晚期乳腺癌中，双重阻断可改善无进展生存期，迎来新纪元。

Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30.

Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.一项 II 期平行分组研究表明，对于作为一线激素治疗的绝经前转移性乳腺癌患者，与单独使用来曲唑治疗的绝经后患者相比，来曲唑加戈舍瑞林治疗具有相当的疗效。

J Clin Oncol. 2010 Jun 1;28(16):2705-11. doi: 10.1200/JCO.2009.26.5884. Epub 2010 Apr 26.

引用本文的文献

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer.解析内分泌治疗耐药的 HER2+/ER+ 乳腺癌的弱点。

Endocrinology. 2023 Nov 2;164(12). doi: 10.1210/endocr/bqad159.

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer.揭示内分泌治疗耐药性HER2+/ER+乳腺癌的脆弱性

bioRxiv. 2023 Aug 22:2023.08.21.554116. doi: 10.1101/2023.08.21.554116.

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. Tucatinib、来曲唑和哌柏西利在既往治疗过的 HR+/HER2+乳腺癌患者中的安全性和疗效。

Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. doi: 10.1158/1078-0432.CCR-23-0117.

Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2.三靶点联合治疗激素受体阳性、HER2 过表达型乳腺癌

Mol Cancer Ther. 2022 Jan;21(1):48-57. doi: 10.1158/1535-7163.MCT-21-0098. Epub 2021 Nov 2.

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.通过抑制CDK4/6克服三阳性乳腺癌的治疗耐药性

Int J Breast Cancer. 2018 Jun 19;2018:7835095. doi: 10.1155/2018/7835095. eCollection 2018.

Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases.乳腺癌人表皮生长因子受体2评分2（+）可疑病例的定量数字图像分析与荧光原位杂交的比较研究

J Pathol Inform. 2015 Jun 3;6:31. doi: 10.4103/2153-3539.158066. eCollection 2015.

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.HER-2+ 转移性乳腺癌一线治疗的进展。

Oncologist. 2012;17(5):631-44. doi: 10.1634/theoncologist.2011-0187. Epub 2012 Apr 20.

HER2 and hormone receptor-positive breast cancer--blocking the right target.人表皮生长因子受体 2 阳性和激素受体阳性乳腺癌——阻断正确的靶点。

Nat Rev Clin Oncol. 2011 May;8(5):307-11. doi: 10.1038/nrclinonc.2010.185. Epub 2010 Dec 14.

Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.拉帕替尼：用于治疗激素受体阳性、HER2 阳性转移性乳腺癌的绝经后妇女。

Drugs. 2010 Jul 30;70(11):1411-22. doi: 10.2165/11204550-000000000-00000.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验